What percentage of patients with suspected tubercular (tuberculosis) pleural effusion will test positive using cartridge-based nucleic acid amplification?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cartridge-Based Nucleic Acid Amplification Testing Positivity in Tubercular Pleural Effusion

Approximately 32-56% of tubercular pleural effusion cases will test positive by cartridge-based nucleic acid amplification testing (CBNAAT) on pleural fluid, with the most robust guideline evidence indicating 56% sensitivity. 1

Diagnostic Performance of CBNAAT in Pleural Fluid

Guideline-Based Sensitivity Data

  • The American Thoracic Society/IDSA/CDC guidelines report that nucleic acid amplification testing (NAAT) performed on pleural fluid demonstrates 56% sensitivity, meaning approximately 56% of true tubercular pleural effusion cases will test positive, with a false-negative rate of 44%. 1

  • The specificity is excellent at 98%, indicating that only about 2% of positive CBNAAT results are false-positives, making a positive test highly reliable for confirming tubercular pleural effusion. 1

Real-World Research Data

Recent research studies corroborate these guideline figures with similar findings:

  • A 2019 Indian study of 75 clinically suspected tubercular pleural effusion cases found CBNAAT positivity in 32% (24/75 patients), which falls within the expected range given the study included both definite and probable cases. 2

  • A 2020 Chinese study reported Xpert MTB/RIF sensitivity of 43.6% in pleural fluid when using culture-positive cases as the reference standard. 3

  • A 2013 study found only 15% sensitivity in pleural fluid specimens, though this represented a smaller cohort. 4

  • A 2020 study evaluating multiple nucleic acid tests reported Xpert MTB/RIF sensitivity of 27.4% in pleural effusion samples from culture-positive tuberculous pleurisy patients. 5

Critical Clinical Implications

Interpretation of Results

  • A positive CBNAAT result can be used as definitive evidence of tubercular pleural effusion because false-positive results are exceedingly rare (only 2%), and treatment should be initiated based on this finding. 1

  • A negative CBNAAT result cannot exclude tubercular pleural effusion because false-negative results occur in 44% of cases, making additional diagnostic testing mandatory when clinical suspicion remains moderate to high. 1

Common Pitfalls to Avoid

  • Do not rely on CBNAAT alone for diagnosis - the low sensitivity means that nearly half of true tubercular pleural effusion cases will have negative CBNAAT results. 1

  • Always perform mycobacterial culture regardless of CBNAAT results, as culture remains essential for definitive diagnosis and drug susceptibility testing, even though it takes 2-6 weeks for results. 1

  • Consider pleural biopsy when CBNAAT is negative - CBNAAT on pleural tissue demonstrates significantly higher sensitivity (85.5%) compared to pleural fluid (43.6%), making tissue sampling more diagnostically valuable. 3

Alternative Diagnostic Approach

  • In high TB prevalence areas, pleural fluid adenosine deaminase (ADA) ≥40 U/L combined with lymphocyte predominance (≥70%) and exudative criteria provides sufficient evidence to diagnose tubercular pleural effusion and initiate treatment, potentially deferring the need for invasive pleural biopsy when CBNAAT is negative. 2

  • Higher ADA levels show significant association with CBNAAT positivity (p=0.001), suggesting that very elevated ADA values increase the likelihood of a positive CBNAAT result. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Rapid diagnosis of pleural tuberculosis by Xpert MTB/RIF assay using pleural biopsy and pleural fluid specimens.

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2015

Research

Xpert® MTB/RIF in pleural fluid for the diagnosis of tuberculosis.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.